NASH Drugs
Oct 14, 2024
6 Promising Late-stage NASH Drugs to Challenge REZDIFFRA’s Supremacy
At present, REZDIFFRA stands as the only approved NASH drug to battle the devastating disease. This once-daily, oral THR-β agonist received a fast-track nod from the US FDA in March 2024, thanks to the impressive outcomes of the Phase III MAESTRO-NASH trial. But with one trailblazer already in the ring, the race is...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
